Patent medicine the patent medicines, some of their makers began replacing the opium tincture laudanum with acetanilide, a particularly toxic non-steroidal anti-inflammatory drug with analgesic as well as antipyretic properties that had been introduced into medical practice under the name "Antifebrin" by A. Cahn and P. Hepp in 1886. But this ingredient change probably killed more of the nostrum's users than the original narcotics did, since acetanilide not only caused an alarming cyanosis due to methemoglobinemia but was later discovered to cause liver and kidney damage. The occasional reports of acetanilide-induced cyanosis prompted the search for supposedly less toxic aniline derivatives, such
Personalized medicine will work based on their genome. The personal genotype can allow physicians to have more detailed information that will guide them in their decision in treatment prescriptions, which will be more cost-effective and accurate. As quoted from the article "Pharmacogenomics: The Promise of Personalised Medicine", “therapy with the right drug at the right dose in the right patient” is a description of how personalized medicine will affect the future of treatment. For instance, tamoxifen used to be a drug commonly prescribed to women with ER+ breast cancer, but 65% of women initially taking it developed resistance. After some research by